CURE Pharmaceutical Holding Corp. announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors. These appointments will expand the size of the board to five with more members expected to be added in first quarter. Bill Yuan has served on CURE's Board of Directors for 2 years and Dr. Gene Salkind has been an advisor and investor in CURE. With more than 20 years of global finance experience, Bill Yuan has held positions with Wall Street's tier one firms including Goldman Sachs (M&A), Morgan Stanley SB (Capital Markets), and Merrill Lynch (Corporate Institutional Asset Management). His leadership, track record and exclusive network of corporate and institutional clients and investors will contribute key building blocks for CURE to achieve the highest level of success.